ENLAZA THERAPEUTICS

Live / Applied — Third extension granted (statement of use) (as of 30 Jan 2026)

What this means for you

Not registered yet, but its 13 Dec 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
97716174
Mark type
Stylized text
Filed
13 Dec 2022
Published for opposition
30 Apr 2024
Attorney of record
Alyssa M. Worsham

Goods and services

  • Class 001 — Chemicals: Reagents for medical research, namely, for therapeutic drug development; antibody reagents for scientific purposes; in-vivo diagnostic reagents for scientific or research use; enzymes for scientific use; cell culture media for use in scientific research for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; active chemical ingredients for use in the manufacture of anti-cancer drugs; laboratory chemicals, namely, an antibody reagent used for the detection of cancerous tumors; antibodies for research use, namely, for therapeutic drug development
  • Class 005 — Pharmaceuticals: Pharmaceutical products, preparations, and substances for the treatment of cancer; cancer therapeutics, namely, anti-cancer preparations; novel cancer therapies, namely, pharmaceutical preparations and substances for the treatment of cancer and tumors; biological preparations and substances for the treatment, diagnosis, detection, and prevention of cancer; pharmaceutical products consisting of covalent protein biologic for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; pharmaceutical products, namely, covalent protein drugs for the treatment of cancer diseases; pharmaceuticals products consisting of synthetic biology enabled covalent protein biologic for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; pharmaceutical products consisting of covalent protein drugs for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals
  • Class 042 — Scientific and technological services: Research and development in the field of covalent protein biologics; medical and scientific research in the field of cancer treatment and diagnosis; pharmaceutical research and development; research and development of pharmaceuticals and biologicals in the field of cancer therapeutics; research and development in the field of synthetic biology enabled covalent therapeutics and covalent protein drugs; research and development for the purpose of selective covalent modification of proteins; research and development in the field of oncology, namely, development of a biotechnology platform to create covalent protein biologics for treating cancer; research and development in the field of covalent protein drugs, namely, development of a platform technology for identification of small-molecule and biologic therapeutics for treating cancer and targeting tumors; conducting clinical trials for others in the field of cancer therapeutics; biotechnology testing services, namely, testing in the field of recombinant protein production and bioconjugation; research and development services in the field of antibody-drug conjugates, T cells, natural killer (NK) cells, and macrophage engaging antibodies; research and development services for the purpose of antibody engineering, namely, custom design and engineering of antibodies

Owner

Prosecution history

  • 31 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 30 Jan 2026 — SOU EXTENSION 3 GRANTED
  • 30 Jan 2026 — SOU EXTENSION 3 FILED
  • 30 Jan 2026 — SOU TEAS EXTENSION RECEIVED
  • 25 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 24 Jul 2025 — SOU EXTENSION 2 GRANTED
  • 24 Jul 2025 — SOU EXTENSION 2 FILED
  • 24 Jul 2025 — SOU TEAS EXTENSION RECEIVED
  • 20 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 20 Feb 2025 — SOU EXTENSION 1 GRANTED
  • 19 Feb 2025 — SOU EXTENSION 1 FILED
  • 19 Feb 2025 — SOU TEAS EXTENSION RECEIVED
  • 20 Aug 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 10 Jul 2024 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
  • 29 May 2024 — EXTENSION OF TIME TO OPPOSE RECEIVED

View this trademark record on Marksy